News & Events

Check out our news section to keep up to date with any upcoming events which we will be attending as well as any exciting news within the pharmaceutical industry.

Vaccine Success!

Amazing news for everyone with the confirmation that AstraZeneca’s COVID-19 vaccine has been approved for emergency supply in the UK by the MHRA, the UK medicines regulator, with the first doses being released today (Dec. 30th 2020) so that vaccinations may begin early in the New Year.As a key supplier of the AZD1222 vaccine to AstraZeneca for clinical trials, everyone at Symbiosis is tremendously proud to… Read More

The Scottish Life Sciences Covid-19 Strategic Response Plan

Symbiosis CEO Colin MacKay is a proud member of the ILG (Life Sciences Industry Leadership Group) and they have just announced their Scottish Life Sciences Covid-19 Strategic Response Plan.Following the outstanding response to Covid19 by the Scottish life sciences sector, the Industry Leadership Group have identified the priority areas of focus for the sector to ensure patients have access to new and… Read More

Investing in our future workforce

We were delighted to see Symbiosis apprentices showcased in The Sunday Times yesterday.The Scottish Government has identified apprenticeships as crucial and the article detailed why apprenticeships are so important for economic success.It also highlighted how Symbiosis apprentices had recently witnessed history in the making as they watched Symbiosis technicians create clinical trial material for Oxford University and AstraZeneca’s breakthrough Covid-19 vaccine, AZD1222.Read… Read More

A vaccine for the whole world

Fantastic news for everyone as a vaccine that Symbiosis has supported is hailed as a “vaccine for the whole world”. #Oxford #AstraZeneca #COVID19 #vaccine has 70.4% average efficacy and 90% if a lower dose used – plus it can be stored at normal fridge temperature (2-8 °C).Symbiosis is proud of its support for the AstraZeneca clinical trials of the AZD1222 vaccine. Part of a world-class team that is leading – and hopefully winning – the global fight against COVID-19. You can read about our involvement here: https://www.symbiosis-pharma.com/news/symbiosis-astrazeneca-sign-supply-agreement-sterile-manufacture-covid-19-vaccine-clinical-trials/Details from… Read More

SUCCESSFUL MHRA REGULATORY INSPECTION FOR SYMBIOSIS

RAPIDLY-GROWING contract manufacturing organisation (CMO) Symbiosis Pharmaceutical Services (Symbiosis), has successfully completed a scheduled inspection by the UK Government regulator, the Medicines and Healthcare products Regulatory Agency (MHRA).Headquartered in Stirling, UK, and specialising in the sterile manufacture of vaccines, pharmaceuticals and biopharmaceuticals for clinical and commercial use, Symbiosis recorded no critical or major observations from the reinspection by the MHRA.In order to… Read More

Life Sciences Innovation and Responding to COVID-19

Scotland’s Minister for Trade, Investment and Innovation, Ivan McKee recently issued a statement to the Scottish Parliament regarding the COVID-19 crisis and Scotland’s life science sector’s support for and response to the COVID-19 pandemic.The accompanying report sets out the work of the sector including examples across test supply chain, vaccine development and repurposing of drugs and aims to provide a snapshot of… Read More

Symbiosis confirms commitment to growth strategy with key appointment

Symbiosis Pharmaceutical Services (Symbiosis), a fast-growing contract manufacturing organisation (CMO) specialising in sterile manufacture of vaccines, pharmaceuticals and biopharmaceuticals, and headquartered in Stirling, UK, has appointed Mr. John McCormick as Chief Operating Officer (COO) and executive member of its Board of Directors.Previously operations development director at Symbiosis, Mr. McCormick has 15 years of experience in the pharmaceutical and biotechnology industry in various… Read More

Symbiosis secures £1 million of growth finance from Allied Irish Bank (GB)

Stirling-based Symbiosis Pharmaceutical Services has secured £1million of finance from Allied Irish Bank (GB) to support its 2020 growth strategy.Symbiosis provides niche, sterile manufacturing services to global biotechnology and pharmaceutical company clients that are developing novel drug therapies and vaccines for use in clinical trials or the commercial market.Symbiosis’s facility at Stirling Innovation Park was purpose built in 2011 to manufacture deliberately… Read More

Symbiosis and AstraZeneca Sign Supply Agreement for Sterile Manufacture of COVID-19 Vaccine for Clinical Trials

Stirling, UK: Symbiosis Pharmaceutical Services, a specialist provider of pharmaceutical and vaccine development services, has announced it has signed a supply agreement with AstraZeneca for sterile manufacture of the COVID-19 recombinant adenovirus vaccine known as AZD1222 for AstraZeneca sponsored clinical trials.Under the agreement, Symbiosis will provide AstraZeneca fast-track access to sterile vaccine drug product manufacturing capacity for clinical trial supply.The agreement follows… Read More

Race for the vaccine

We think this is a great overview and general summary of the challenges and process of making a new drug in relation to the current coronavirus crisis:On 16 March, a needle was put in the arm of a Seattle woman who may change the world.Jennifer Haller had a candidate vaccine against coronavirus injected into her bloodstream – the first human trial aimed… Read More

Get In Touch.


By ticking the box and clicking “Submit” below, you consent to receiving thought leadership, industry news, and invitations by email or other electronic means, which Symbiosis Pharmaceutical Services believes may be of value to you, relevant to your work and tailored to your professional profile and interests. This may include promotional information on products, services and events provided or organised by Symbiosis Pharmaceutical Services. By clicking the "Submit” button, you confirm that the information you have provided above is correct, and you agree to Symbiosis' processing of your personal data, including its transfer internationally and to third parties, in accordance with it's privacy policy.